Brought to you by 
Fondazione licenses rare genetic disease agents to Glaxo
12 Apr 2018
Executive Summary
Fondazione Telethon (Italian nonprofit organization that supports genetic disease research) and the Fondazione San Raffaele del Monte Tabor (scientific institute) have granted GlaxoSmithKline PLC exclusive worldwide rights to their Phase I/II gene therapeutic for adenosine deaminase deficiency-severe combined immune deficiency (ADA-SCID; also known as the bubble boy syndrome).
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Fondazione licenses rare genetic disease agents to Glaxo
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice